Crocodile Capital Partners GmbH Sells 12,163 Shares of BioNTech SE Sponsored ADR $BNTX

Crocodile Capital Partners GmbH lessened its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 41.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,423 shares of the company’s stock after selling 12,163 shares during the period. BioNTech comprises approximately 1.1% of Crocodile Capital Partners GmbH’s portfolio, making the stock its 7th biggest position. Crocodile Capital Partners GmbH’s holdings in BioNTech were worth $1,713,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Integrated Wealth Concepts LLC purchased a new position in BioNTech in the second quarter valued at about $39,000. Farther Finance Advisors LLC raised its holdings in shares of BioNTech by 31.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after purchasing an additional 118 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after purchasing an additional 506 shares during the last quarter. Vestcor Inc acquired a new stake in shares of BioNTech in the 4th quarter valued at $153,000. Finally, Rockefeller Capital Management L.P. boosted its holdings in BioNTech by 328.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after purchasing an additional 1,423 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BioNTech

In related news, CEO Ugur Sahin sold 72,000 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the transaction, the chief executive officer directly owned 108,209 shares in the company, valued at $10,521,161.07. This represents a 39.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 744,000 shares of company stock worth $73,301,215 over the last 90 days. Insiders own 19.20% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX opened at $92.06 on Friday. The company has a market capitalization of $23.28 billion, a PE ratio of -11.76 and a beta of 1.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company’s fifty day moving average price is $99.04 and its 200 day moving average price is $95.16.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.60) earnings per share. As a group, analysts expect that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have commented on BNTX. Morgan Stanley lowered their target price on shares of BioNTech from $115.00 to $114.00 and set an “overweight” rating on the stock in a research report on Wednesday. Argus initiated coverage on BioNTech in a research report on Thursday. They issued a “hold” rating for the company. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. UBS Group reissued a “buy” rating on shares of BioNTech in a report on Wednesday, September 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $125.69.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.